Emmanuel Garcion

List of Publications by Year
in descending order

57 papers	3,942 citations	182225 30 h-index	198040 52 g-index
57 all docs	57 docs citations	57 times ranked	6535 citing authors

#	Article	IF	Citations
1	Curdlanâ€“Chitosan Electrospun Fibers as Potential Scaffolds for Bone Regeneration. Polymers, 2021, 13, 526.	2.0	19
2	LentiRILES, a miRNA-ON sensor system for monitoring the functionality of miRNA in cancer biology and therapy. RNA Biology, 2021, 18, 198-214.	1.5	4
3	Nanoparticle-containing electrospun nanofibrous scaffolds for sustained release of SDF-1Î±. International Journal of Pharmaceutics, 2021, 610, 121205.	2.6	13
4	Intracellular trafficking and functional monitoring of miRNA delivery in glioblastoma using lipopolyplexes and the miRNA-ON RILES reporter system. Journal of Controlled Release, 2020, 327, 429-443.	4.8	16
5	Synthesis, Characterization, and In Vitro Studies of an Reactive Oxygen Species (ROS)-Responsive Methoxy Polyethylene Glycol-Thioketal-Melphalan Prodrug for Glioblastoma Treatment. Frontiers in Pharmacology, 2020, 11, 574.	1.6	21
6	Aerogel sponges of silk fibroin, hyaluronic acid and heparin for soft tissue engineering: Composition-properties relationship. Carbohydrate Polymers, 2020, 237, 116107.	5.1	24
7	Targeting Tumor Associated Macrophages to Overcome Conventional Treatment Resistance in Glioblastoma. Frontiers in Pharmacology, 2020, 11, 368.	1.6	50
8	Rapamycin-Loaded Lipid Nanocapsules Induce Selective Inhibition of the mTORC1-Signaling Pathway in Glioblastoma Cells. Frontiers in Bioengineering and Biotechnology, 2020, 8, 602998.	2.0	7
9	Rhenium-188 Labeled Radiopharmaceuticals: Current Clinical Applications in Oncology and Promising Perspectives. Frontiers in Medicine, 2019, 6, 132.	1.2	96
10	Potential for Nuclear Medicine Therapy for Glioblastoma Treatment. Frontiers in Pharmacology, 2019, 10, 772.	1.6	31
11	Reversing the Tumor Target: Establishment of a Tumor Trap. Frontiers in Pharmacology, 2019, 10, 887.	1.6	15
12	Rethinking Alkylating(-Like) Agents for Solid Tumor Management. Trends in Pharmacological Sciences, 2019, 40, 342-357.	4.0	31
13	MicroRNA-Based Drugs for Brain Tumors. Trends in Cancer, 2018, 4, 222-238.	3.8	54
14	Development of a non-toxic and non-denaturing formulation process for encapsulation of SDF-1Î± into PLGA/PEG-PLGA nanoparticles to achieve sustained release. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 125, 38-50.	2.0	39
15	Hybrid Gd³⁺/cisplatin cross-linked polymer nanoparticles enhance platinum accumulation and formation of DNA adducts in glioblastoma cell lines. Biomaterials Science, 2018, 6, 2386-2409.	2.6	28
16	Proteinâ€“polysaccharide complexes for enhanced protein delivery in hyaluronic acid templated calcium carbonate microparticles. Journal of Materials Chemistry B, 2017, 5, 7360-7368.	2.9	14
17	Characterization of the distribution, retention, and efficacy of internal radiation of 188Re-lipid nanocapsules in an immunocompromised human glioblastoma model. Journal of Neuro-Oncology, 2017, 131, 49-58.	1.4	20
18	Locoregional Confinement and Major Clinical Benefit of ¹⁸⁸Re-Loaded CXCR4-Targeted Nanocarriers in an Orthotopic Human to Mouse Model of Glioblastoma. Theranostics, 2017, 7, 4517-4536.	4.6	46

#	Article	IF	Citations
19	Low oxygen tension reverses antineoplastic effect of iron chelator deferasirox in human glioblastoma cells. BMC Cancer, 2016, 16, 51.	1.1	13
20	Iron metabolism: a double-edged sword in the resistance of glioblastoma to therapies. Trends in Endocrinology and Metabolism, 2015, 26, 322-331.	3.1	67
21	Nanomedicine to overcome radioresistance in glioblastoma stem-like cells and surviving clones. Trends in Pharmacological Sciences, 2015, 36, 236-252.	4.0	44
22	Tumour targeting of lipid nanocapsules grafted with cRGD peptides. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 87, 152-159.	2.0	22
23	Inhibition of ectopic glioma tumor growth by a potent ferrocenyl drug loaded into stealth lipid nanocapsules. Nanomedicine: Nanotechnology, Biology, and Medicine, 2014, 10, 1667-1677.	1.7	38
24	Effect of particle size on the biodistribution of lipid nanocapsules: Comparison between nuclear and fluorescence imaging and counting. International Journal of Pharmaceutics, 2013, 453, 594-600.	2.6	54
25	Hypoxia-induced expression of VE-cadherin and filamin B in glioma cell cultures and pseudopalisade structures. Journal of Neuro-Oncology, 2013, 113, 239-249.	1.4	18
26	Transferrin Adsorption onto PLGA Nanoparticles Governs Their Interaction with Biological Systems from Blood Circulation to Brain Cancer Cells. Pharmaceutical Research, 2012, 29, 1495-1505.	1.7	95
27	Administration-dependent efficacy of ferrociphenol lipid nanocapsules for the treatment of intracranial 9L rat gliosarcoma. International Journal of Pharmaceutics, 2012, 423, 55-62.	2.6	36
28	Lipid Nanocapsules Loaded with Rhenium-188 Reduce Tumor Progression in a Rat Hepatocellular Carcinoma Model. PLoS ONE, 2011, 6, e16926.	1.1	38
29	In vitro expansion of human glioblastoma cells at non-physiological oxygen tension irreversibly alters subsequent in vivo aggressiveness and AC133 expression. International Journal of Oncology, 2011, 40, 1220-9.	1.4	7
30	Tumor eradication in rat glioma and bypass of immunosuppressive barriers using internal radiation with 188Re-lipid nanocapsules. Biomaterials, 2011, 32, 6781-6790.	5.7	63
31	The Importance of the Stem Cell Marker Prominin-1/CD133 in the Uptake of Transferrin and in Iron Metabolism in Human Colon Cancer Caco-2 Cells. PLoS ONE, 2011, 6, e25515.	1.1	63
32	The importance of endo-lysosomal escape with lipid nanocapsules for drug subcellular bioavailability. Biomaterials, 2010, 31, 7542-7554.	5.7	123
33	In vivo evaluation of intracellular drug-nanocarriers infused into intracranial tumours by convection-enhanced delivery: distribution and radiosensitisation efficacy. Journal of Neuro-Oncology, 2010, 97, 195-205.	1.4	43
34	Positively-Charged, Porous, Polysaccharide Nanoparticles Loaded with Anionic Molecules Behave as â€˜Stealthâ€™ Cationic Nanocarriers. Pharmaceutical Research, 2010, 27, 126-133.	1.7	48
35	Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery. Nanomedicine, 2010, 5, 287-306.	1.7	264
36	External irradiation models for intracranial 9L glioma studies. Journal of Experimental and Clinical Cancer Research, 2010, 29, 142.	3.5	14

#	Article	IF	Citations
37	Cancer stem cells: Beyond Kochâ€™s postulates. Cancer Letters, 2009, 278, 3-8.	3.2	22
38	Abstract A60: Targeting brain tumor stem cells. , 2009, , .		0
39	Lipid nanocapsules loaded with an organometallic tamoxifen derivative as a novel drug-carrier system for experimental malignant gliomas. Journal of Controlled Release, 2008, 130, 146-153.	4.8	113
40	Lipid Nanocapsules for Intracellular Drug Delivery of Anticancer Drugs. Journal of Nanoscience and Nanotechnology, 2007, 7, 4612-4617.	0.9	47
41	Lipid nanocapsules for intracellular drug delivery of anticancer drugs. Journal of Nanoscience and Nanotechnology, 2007, 7, 4612-7.	0.9	13
42	Influence of polysaccharide coating on the interactions of nanoparticles with biological systems. Biomaterials, 2006, 27, 108-118.	5.7	178
43	Evaluation of particulate systems supporting tumor cell fractions in a preventive vaccination against intracranial rat glioma. Journal of Neurosurgery, 2006, 105, 745-752.	0.9	3
44	A new generation of anticancer, drug-loaded, colloidal vectors reverses multidrug resistance in glioma and reduces tumor progression in rats. Molecular Cancer Therapeutics, 2006, 5, 1710-1722.	1.9	179
45	Tissue Distribution of Indinavir Administered as Solid Lipid Nanocapsule Formulation in mdr1a (+/+) and mdr1a (â^'/â^') CF-1 Mice. Pharmaceutical Research, 2005, 22, 1898-1905.	1.7	42
46	Vitamin D, A Neuroactive Hormone: From Brain Development to Pathological Disorders. , 2005, , 1779-1789.		1
47	Generation of an environmental niche for neural stem cell development by the extracellular matrix molecule tenascin C. Development (Cambridge), 2004, 131, 3423-3432.	1.2	279
48	The extracellular matrix glycoprotein Tenascin-C is expressed by oligodendrocyte precursor cells and required for the regulation of maturation rate, survival and responsiveness to platelet-derived growth factor. European Journal of Neuroscience, 2004, 20, 2524-2540.	1.2	92
49	In vitro study of GDNF release from biodegradable PLGA microspheres. Journal of Controlled Release, 2004, 95, 463-475.	4.8	108
50	RNA mutagenesis and sporadic prion diseases. Journal of Theoretical Biology, 2004, 230, 271-274.	0.8	5
51	Heparin stabilizes FGF-2 and modulates striatal precursor cell behavior in response to EGF. Experimental Neurology, 2004, 188, 408-420.	2.0	57
52	Treatment of experimental autoimmune encephalomyelitis in rat by 1,25-dihydroxyvitamin D3 leads to early effects within the central nervous system. Acta Neuropathologica, 2003, 105, 438-448.	3.9	97
53	La tÃ©nascine-C : une molÃ©cule de la matrice extracellulaire impliquÃ©e dans le dÃ©veloppement du systÃ¨me nerveux central. Medecine/Sciences, 2002, 18, 982-988.	0.0	0
54	New clues about vitamin D functions in the nervous system. Trends in Endocrinology and Metabolism, 2002, 13, 100-105.	3.1	759

#	Article	IF	Citations
55	Knockout mice reveal a contribution of the extracellular matrix molecule tenascin-C to neural precursor proliferation and migration. Development (Cambridge), 2001, 128, 2485-2496.	1.2	196
56	Expression of inducible nitric oxide synthase during rat brain inflammation: Regulation by 1,25-dihydroxyvitamin D3. , 1998, 22, 282-294.		171
57	Expression of inducible nitric oxide synthase during rat brain inflammation: Regulation by 1,25-dihydroxyvitamin D3. , 1998, 22, 282.		2